- Home
- VERU vs CNTY Comparison
VERU vs CNTY Comparison
Compare VERU & CNTY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VERU | CNTY |
|---|---|---|
| Founded | 1971 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Hotels/Resorts |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 48.2M | 40.8M |
| IPO Year | 1996 | 1996 |
Fundamental Metrics
Financial Performance| Metric | VERU | CNTY |
|---|---|---|
| Price | $2.92 | $1.42 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $22.50 | $3.00 |
| AVG Volume (30 Days) | ★ 5.2M | 49.6K |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 51.31 |
| EPS | ★ N/A | N/A |
| Revenue | $16,296,958.00 | ★ $430,529,000.00 |
| Revenue This Year | N/A | $7.17 |
| Revenue Next Year | N/A | $3.28 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 10.82 |
| 52 Week Low | $0.36 | $1.23 |
| 52 Week High | $7.33 | $2.85 |
Technical Indicators
Market Signals| Indicator | VERU | CNTY |
|---|---|---|
| Relative Strength Index (RSI) | 53.55 | 51.01 |
| Support Level | $2.15 | $1.40 |
| Resistance Level | $3.68 | $1.47 |
| Average True Range (ATR) | 0.67 | 0.07 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 16.09 | 53.33 |
Price Performance
Historical ComparisonAbout VERU Veru Inc.
Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.
About CNTY Century Casinos Inc.
Century Casinos Inc is a casino entertainment company that develops and operates gaming establishments as well as related lodging, restaurants, horse racing (including off-track betting), and entertainment facilities in North America. The company has five reportable segments based on the geographical locations in which its casinos operate; US East, US Midwest, US West, Canada, and Poland.